Pharma

Photo
19.09.2025 • NewsPharma

Roche to Acquire 89Bio in $3.5 Billion Deal

Acquisition supports Roche’s strategy as it enhances the company’s portfolio in cardiovascular, renal, and metabolic diseases (CVRM) and offers optionality for future combination development.

Photo
• 17.09.2025 • NewsPharma

Stability in Motion

Amid global uncertainty, Bayer Pharma, led by Stefan Oelrich, pursues strategic transformation to boost resilience, drive innovation, and secure sustainable growth in a changing healthcare landscape.

Photo
10.09.2025 • News

Symeres Acquires DGr Pharma

CRDMO Symeres has acquired DGr Pharma, expanding its capabilities with DGr Pharma’s regulatory and consultancy expertise to provide more comprehensive drug development services.

Photo
17.06.2025 • NewsBioprocessing

BASF Opens New GMP Center in Michigan, US

BASF has opened a new Good Manufacturing Practice (GMP) Solution Center in Wyandotte, Michigan, to support the supply of bioprocessing ingredients and excipients for the biopharma and pharmaceutical industries.

Photo
14.05.2025 • TopicsPharma

Pharma Outlook 2025

The environment for pharma in 2025 is diverse and challenging: New treatment options are being brought to market in ever shorter cycles.

Photo
18.09.2023 • NewsStrategy

Intelligent Engineering for Optimized Pharma Manufacturing

The Covid pandemic and its repercussions have changed the pharmaceutical industry and the healthcare markets. Richard Stedman, the CEO of ACG Engineering, discusses the lessons learned from the global supply chain disruptions and how innovative equipment helps pharma manufacturers overcome the challenges.

Photo
17.05.2023 • NewsStrategy

Navigating Uncertainty in the Biopharma Market

Biopharma companies are facing funding challenges in 2023 as interest rates rise and investors are becoming more risk adverse. There is hope on the horizon, say some analysts, while others project a prolonged slump due to inflation and global instability. Established pharmaceutical companies are often seen as safer investments, with larger developers expected to perform well in 2023, especially if litigation threats against drugs like Zantac disappear. However, concerns about revenue gaps continue for big companies like GSK and Sanofi, and their strategy and leadership will be closely monitored in the coming months.

Photo
21.03.2023 • News

Global Pharma Reduces Marketing Staff in India

As part of what seems to be a general pattern of staff reductions in the pharmaceutical industry worldwide, a growing number of Western drugmakers are downsizing their sales and marketing presence in India.

306 more articles

Free Expert Insights

Dual‑Targeting Breakthroughs
Advancements in Bispecific Antibody Development

Dual‑Targeting Breakthroughs

Unlock the latest breakthroughs in bispecific antibody development! Download Wiley’s free Expert Insights eBook to explore cutting-edge dual-targeting strategies, advanced purification methods, and bioanalytical technologies transforming immunotherapy and cancer treatment.